Penumbra's Thunderbolt Cleared by the FDA

Research evidence excerpt

Penumbra's Thunderbolt Cleared by the FDA

H O T C O M M E N T

J u n e 1 1 , 2 0 2 6

Boston Scientific Corp. (BSX) Overweight

CONCLUSION PRICE: US$48.34

This afternoon, Penumbra announced FDA clearance of Thunderbolt which is the TARGET: US$90.00

company's first CAVT product for acute ischemic stroke. The approval process took longer ~27x our 2026E EPS of $3.38

than we initially expected, but we do anticipate meaningful trialing through the back half

of 2026 driven by the company's long-standing footprint in stroke centers and success of Matt O'Brien

Sr. Research Analyst, Piper Sandler & Co.other CAVT products. Furthermore, we also anticipate results from the THUNDER trial will 312 267-5080, matthew.obrien@psc.com

be presented at an upcoming stroke-related conference now that the device is cleared.

Samantha Munoz, Ph.D.

This launch should provide a meaningful growth tailwind for BSX following the transaction's Research Analyst, Piper Sandler & Co.

expected close in 2H26 and help assuage concerns about Boston's top-line growth rate 212 284-9342, samantha.munoz@psc.com

the next couple of years. Reiterate OW rating. Anna Runci

Research Analyst, Piper Sandler & Co.

PEN: Neutral, $374 PT reflects acquisition price. Risks: Competition, market growth, clinical 212 466-7905, anna.runci@psc.com

& regulatory delays, acquisition falling through.

Related Companies: Share Price:

PEN 319.34

Piper Sandler & Co. is advising MiRus, LLC on its Strategic Investment from Boston

Scientific Corporation RISKS TO ACHIEVEMENT OF

PT & RECOMMENDATION

Clinical & regulatory delays, reimbursement,

pricing pressure, leverage.

COMPANY DESCRIPTION

Price Performance - 1 YearBoston Scientific develops and manufactures interventional medical devices.

USD

Jun-25 Aug-25 Oct-25 Dec-25 Feb-26 Apr-26 Jun-26